Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T22:19:08.516Z.
Calculation as of: 2026-10-06T22:19:08.516Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 123a3ec60dc6afba088f2eb2877889c71bba8362c46900388a9f6a500465d062
PE RATIO
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 10x Genomics, Inc. (TXG) | $10.24B | N/A | N/A | N/A | N/A |
| Molina Healthcare, Inc. (MOH)vs › | $10.19B | 1027.21 | 232.01 | 88.58 | 62.84 |
| Globus Medical, Inc. (GMED)vs › | $10.31B | 19.65 | 23.15 | 68.05 | 56.59 |
| ImmunityBio, Inc. (IBRX)vs › | $10.15B | N/A | N/A | N/A | N/A |
| Align Technology, Inc. (ALGN)vs › | $10.13B | 24.56 | 29.33 | 36.97 | 43.63 |
| Twist Bioscience Corporation (TWST)vs › | $10.40B | N/A | N/A | N/A | N/A |
| The Ensign Group, Inc. (ENSG)vs › | $10.03B | 26.97 | 30.73 | 30.61 | 27.70 |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $9.93B | 44.71 | 34.03 | 32.06 | 21.08 |
| Repligen Corporation (RGEN)vs › | $9.87B | 239.53 | 2667.34 | 1448.16 | 807.09 |
| Universal Health Services, Inc. (UHS)vs › | $10.72B | 7.26 | 8.55 | 11.98 | 12.10 |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$80.66
Forward EPS (Est.)
$-0.74
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
